Beam Therapeutics presented its base-editing pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, emphasizing its lead program BEAM-302 for alpha-1 antitrypsin deficiency (AATD). The company reported that patients treated at a 60-milligram dose achieved over 93% of the minimum protective serum alpha-1 antitrypsin levels, rising from baseline levels of 4 to 6 micromolar to over 20 micromolar during illness. The Phase 1/2 study involved 30 patients across 16 sites in six countries, demonstrating a precise, single-base gene correction without double-stranded DNA breaks—a key advantage over earlier CRISPR technologies, as CEO John Evans noted during the presentation.
Beam Therapeutics Highlights Base Editing Lead at Cantor Conference
Beam Therapeutics reported progress on its base-editing program BEAM-302 for alpha-1 antitrypsin deficiency, with clinical data showing efficacy in raising protective serum levels, while outlining timelines for other programs and financial runway.
SL
Sophie Laurent · FX & Rates Desk · 20 Sept 2026 · 09:57 · 1 min de lectura
Este artículo fue producido con asistencia de IA y editado por un periodista de Finance Review Daily.
ADVERTISEMENT
SL
Escrito por
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
Más de Sophie Laurent →
